Radius Health (RDUS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Radius Health, Inc.: Third Quarter 2021 Results
November 8, 2021 8:00 AM ESTTYMLOS® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenueATOM Pivotal Study evaluating abaloparatide-SC for use in males with osteoporosis met primary and key secondary endpoints; sNDA filing is expected Q1, 2022Resubmitted abaloparatide-SC to the European Medicines Agency (EMA) on November 4, 2021wearABLe Pivotal Study (abaloparatide-TD) topline readout remains on track for Q4, 2021EMERALD Pivotal Study evaluating elacestrant in breast cancer was positive as a monotherapy vs.... More
